October 18, 2006 -- Regeneron signed a collaboration with Bayer to develop VEGF Trap drugs for eye diseases; Trubion placed 4 million shares at $13 each in a successful IPO; Sanofi-Aventis received FDA approval of Taxotere for head and neck cancer; Targeted Genetics was issued a patent for its use of adeno-associated vectors to deliver genes; Santarus sold the OTC version of Zegerid to Schering-Plough; Endo Pharma sank following news the FDA eased the path for competition to the Lidoderm pain patch; and Introgen reported positive data for Advexin p53. The Centient Biotech 200™ rose 19 points to 3967, a rise of .49%, putting it in positive territory for 2006. More details...
